Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

Abstract

Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal. Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS). Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature. Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.

Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study

“… 44 , 45 Furthermore, data from a cost-consequences model predicted that, in patients with CAP who responded to treatment, more would be discharged early with ceftaroline fosamil than with ceftriaxone (30.6% versus 26.1%). 46 Of note, in the subgroup of patients with pneumococcal pneumonia, ceftaroline fosamil was cost-saving versus ceftriaxone by 1.2%, while significantly increasing the number of patients achieving initial antibiotic treatment success and early discharge (32.1% versus 24.6%).…”

Antibiotic Strategies for Severe Community-Acquired Pneumonia

“…Moreover, in the subgroup analysis of pneumococcal pneumonia, ceftaroline was significantly cost-saving (minus 1.2% compared with ceftriaxone) and substantially reduced hospitalization length (32.1 vs. 24.6% of patients early discharged with ceftaroline and ceftriaxone, respectively). 100…”

“…Antibacterial agents in the pipeline for severe community-acquired pneumonia MSSA, MRSA, hVISA, VISA, and VRSA, daptomycin nonsusceptible S. aureus, linezolid resistant S. aureus, non-ESBL or AmpC-producing Enterobacteriaceae, Haemophilus spp., and Moraxella catarrhalis Antibiotic Strategies in Severe CAPBassetti et al 191 length (32.1 vs. 24.6% of patients early discharged with ceftaroline and ceftriaxone, respectively) 100. …”